These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26423401)

  • 1. PMS2 expression in epithelial ovarian cancer is posttranslationally regulated by Akt and essential for platinum-induced apoptosis.
    Jia J; Wang Z; Cai J; Zhang Y
    Tumour Biol; 2016 Mar; 37(3):3059-69. PubMed ID: 26423401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of AKT sensitizes chemoresistant ovarian cancer cells to cisplatin by abrogating S and G2/M arrest.
    Zhang D; Piao HL; Li YH; Qiu Q; Li DJ; Du MR; Tsang BK
    Exp Mol Pathol; 2016 Jun; 100(3):506-13. PubMed ID: 27163202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
    Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
    BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.
    Kritsch D; Hoffmann F; Steinbach D; Jansen L; Mary Photini S; Gajda M; Mosig AS; Sonnemann J; Peters S; Melnikova M; Thomale J; Dürst M; Runnebaum IB; Häfner N
    Int J Cancer; 2017 Oct; 141(8):1600-1614. PubMed ID: 28670762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
    Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
    Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer.
    Dai Y; Jin S; Li X; Wang D
    Oncotarget; 2017 Jan; 8(1):1354-1368. PubMed ID: 27935869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of fatty acid synthase in Middle Eastern epithelial ovarian carcinoma activates AKT and Its inhibition potentiates cisplatin-induced apoptosis.
    Uddin S; Jehan Z; Ahmed M; Alyan A; Al-Dayel F; Hussain A; Bavi P; Al-Kuraya KS
    Mol Med; 2011; 17(7-8):635-45. PubMed ID: 21442130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JNK- and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells.
    Zhao Z; Wang J; Tang J; Liu X; Zhong Q; Wang F; Hu W; Yuan Z; Nie C; Wei Y
    Biochem J; 2012 Jun; 444(2):291-301. PubMed ID: 22394200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.
    Xiao M; Cai J; Cai L; Jia J; Xie L; Zhu Y; Huang B; Jin D; Wang Z
    J Ovarian Res; 2017 Apr; 10(1):24. PubMed ID: 28376831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer.
    Fedoseienko A; Wieringa HW; Wisman GB; Duiker E; Reyners AK; Hofker MH; van der Zee AG; van de Sluis B; van Vugt MA
    PLoS One; 2016; 11(10):e0165385. PubMed ID: 27788210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
    Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
    Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Theaflavin-3, 3'-digallate induces apoptosis and G2 cell cycle arrest through the Akt/MDM2/p53 pathway in cisplatin-resistant ovarian cancer A2780/CP70 cells.
    Tu Y; Kim E; Gao Y; Rankin GO; Li B; Chen YC
    Int J Oncol; 2016 Jun; 48(6):2657-65. PubMed ID: 27082635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
    Asselin E; Mills GB; Tsang BK
    Cancer Res; 2001 Mar; 61(5):1862-8. PubMed ID: 11280739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.
    Long J; Zhu JY; Liu YB; Fu K; Tian Y; Li PY; Yang WQ; Yang SY; Yin JY; Yin G; Zhang Y
    Gynecol Oncol; 2018 May; 149(2):341-349. PubMed ID: 29572031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptotic function of human PMS2 compromised by the nonsynonymous single-nucleotide polymorphic variant R20Q.
    Marinovic-Terzic I; Yoshioka-Yamashita A; Shimodaira H; Avdievich E; Hunton IC; Kolodner RD; Edelmann W; Wang JY
    Proc Natl Acad Sci U S A; 2008 Sep; 105(37):13993-8. PubMed ID: 18768816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
    Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
    Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ganoderma lucidum exerts anti-tumor effects on ovarian cancer cells and enhances their sensitivity to cisplatin.
    Zhao S; Ye G; Fu G; Cheng JX; Yang BB; Peng C
    Int J Oncol; 2011 May; 38(5):1319-27. PubMed ID: 21399867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of CXCR4 is significantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in epithelial ovarian cancer.
    Li J; Jiang K; Qiu X; Li M; Hao Q; Wei L; Zhang W; Chen B; Xin X
    BMB Rep; 2014 Jan; 47(1):33-8. PubMed ID: 24209634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
    Fraser M; Bai T; Tsang BK
    Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mismatch repair and treatment resistance in ovarian cancer.
    Helleman J; van Staveren IL; Dinjens WN; van Kuijk PF; Ritstier K; Ewing PC; van der Burg ME; Stoter G; Berns EM
    BMC Cancer; 2006 Jul; 6():201. PubMed ID: 16879751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.